CooperVision’s MyDays Energys contact lenses hit US market

Article

First 1-Day Lens that combines DigitalBoost and Aquaform technologies designed to deliver comfort for ‘always on’ digital lifestyles

Photo courtesy of © BullRun

Photo courtesy of © BullRun

On March 1, 2023, CooperVision announced that MyDay Energys, the latest addition to the MyDay contact lens line, is now available to eye care practitioners across the United States.1 This is the global debut of the lenses, which are designed to address symptoms of digital eye strain.

MyDay Energys is the first and only 1-day contact lens that combines CooperVision’s aspheric design and material technology to help tiredness and dryness associated with digital eye strain.2 The single vision aspheric design delivers a +0.3D boost of power, aimed to ease strain on eye muscles allowing the wearer to shift focus from on screen to off screen with less effort.3 CooperVision also incorporated its Aquaform Technology, which hydrates MyDay Energys lenses to twice their weight in water4 for natural wettability and comfort, helping eyes feel less dry.

Around 75% of patients from a clinical study said their eyes stay comfortable and relaxed throughout the day—despite frequently viewing digital devices2—while wearing MyDay Energys. Additionally, 80% of wearers said they had less eye fatigue when wearing MyDay Energys, 74% of patients said their vision was less blurry.1

“The average American now spends more than seven hours per day looking at screens,4 with more than half using two or more devices simultaneously.5 Our ability to anticipate this evolution of digital usage and increase in 1-day preference allowed us to be first to market with such an inventive lens,” Michele Andrews, OD, vice president of professional and government affairs, in the Americas at CooperVision, said in a press release.1 “Based on enthusiastic feedback from trial customers, we expect U.S. eye care professionals and contact-lens wearers to widely embrace MyDay Energys.”

MyDay Energys lenses are part of CooperVision’s plastic neutrality initiative, in partnership with Plastic Bank, which recovers plastic from oceans across the globe. To date, the partnership has created an environmental impact equivalent to 130.5 million plastic bottles recovered from oceans.5

For more information, visit the MyDay Energys practitioner page.

References
  1. CooperVision’s Latest Innovation, MyDay Energys® Contact Lenses, Make U.S. Debut. CooperVision. Accessed March 1, 2023. https://coopervision.com/our-company/news-center/press-release/coopervision-latest-innovation-myday-energys-contact-lenses
  2. ‌CVI data on file 2018. Prospective, multi-center (5 US sites), open label, bilateral wear, one week dispensing study with MyDay Energys. N=77 habitual soft CL wearers. Patients slightly agree/agree/strongly agree.
  3. Kajita M et al. Changes in accommodative micro-fluctuations after wearing contact lenses of different optical designs. Cont Lens Ant Eye (2020) In Press https://doi.org/10.1016/j.clae.2020.03.003
  4. Digital 2023: The United States of America. Datareportal. Consumption of different digital media types may occur concurrently.  https://datareportal.com/reports/digital-2023-united-states-of-america. Accessed 9 February 2023.
  5. CooperVision. CooperVision. Accessed March 1, 2023. https://sustainability.coopervision.com/?_ga=2.25408639.351389498.1677689743-1747875558.1677689743

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.